The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies

Diagnosis and dosages for the five patients studied

Sex		Diagnosis		Original dose (g/y)		Final dose (g/y)		Original infusion time (h/y)	Final infusion time (h/y)	Final infusion schedule (g/weeks)	Days in 3 month period at maximum strength (from daily diaries)
Sex		Diagnosis		Original dose (g/y)		Final dose (g/y)		Original infusion time (h/y)	Final infusion time (h/y)	Final infusion schedule (g/weeks)	Original schedule (%)^1-150	Final schedule (%)^1-151
M	MMN	768	816	768	119	48/3	45	0
M	MMN	720	1275	192	170	72/3	30	0
F	MMN	504	936	336	130	72/4	30	4
F	PMDN	1248	1728	364	252	48/2	51	18
F	MMSDN	480	442	30	48	36/4	26	0

↵1-150 After first three infusions an original schedule.
↵1-151 Last three months; now stable.
MMN=multifocal motor neuropathy; PMDN=pure motor demyelinating neuropathy; MMSDN=mixed motor and sensory demyelinating neuropathy;
SAN=sensory ataxic neuropathy.

This Article

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies

This Article

Latest from Practical Neurology

BMJ Careers - Latest Neurology and Neurosurgery jobs